WeVote
Log In

Bill

Bill

HB 321

Pharmacy Benefits Managers – Definition of Purchaser and Alteration of Application of Law

2025 Regular Session Introduced by Tiffany Alston and 19 co-sponsors

Maryland bill redefines PBM purchaser status and alters regulatory application, likely expanding oversight of pharmaceutical benefit manager practices affecting drug pricing and pharmacy operations.

Hearing 3/27 at 1:00 p.m.
0
WeVote Research Nonpartisan
Bill Summary · HB 321

Legislative bill overview

HB 321 modifies Maryland's definition of "purchaser" in pharmacy benefits manager (PBM) regulations and alters how existing PBM oversight laws apply to certain entities. The bill appears designed to expand regulatory scope or change which organizations fall under PBM regulation, though the specific definitional changes require examination of the bill's full text.

Why is this important

PBMs act as intermediaries between insurers, pharmacies, and patients, controlling drug formularies, reimbursement rates, and access. How they're defined and regulated directly affects drug pricing, pharmacy profitability, and patient medication access. Narrowing or broadening the definition of "purchaser" can either strengthen consumer protections or create regulatory gaps depending on the direction of change.

Potential points of contention

  • Pharmacy industry support vs. insurer concerns: Community pharmacies often support expanded PBM regulation, while insurers and large PBM corporations oppose restrictions on their operations
  • Definitional scope ambiguity: Changes to "purchaser" definitions could unintentionally exempt certain PBM activities or create compliance confusion across the industry
  • Cost implications: PBM regulatory changes may increase administrative costs that could be passed to consumers through higher premiums or copays, or alternatively reduce PBM profits at industry expense

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.